Samuele Lillini

Title: Samuele Lillini: Innovator in PARP Inhibitors

Introduction

Samuele Lillini is a prominent inventor based in Rome, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as inhibitors of poly(ADP-ribose) polymerase (PARP). His work is crucial for advancing treatments for various diseases, including cancer and neurodegenerative disorders.

Latest Patents

Samuele Lillini holds a patent for "Pyridazinone derivatives as PARP inhibitors." This invention relates to compounds that are effective in treating a range of conditions, including cancer, inflammatory diseases, and cardiovascular diseases. The patent encompasses compounds of formula (I) and their pharmaceutically acceptable salts or tautomers, which are designed to inhibit PARP activity.

Career Highlights

Lillini is associated with the Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., where he has been instrumental in research and development. His innovative approach to drug design has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Throughout his career, Samuele Lillini has collaborated with notable colleagues, including Danila Branca and Gabriella Dessole. These partnerships have enhanced the scope and impact of his research.

Conclusion

Samuele Lillini's contributions to the field of PARP inhibitors highlight his role as an influential inventor in the medical research community. His work continues to pave the way for new therapeutic strategies in treating complex diseases.